CanRIO Member Publications

Accepted manuscript in The Journal of Rheumatology. Details to follow. Read More

Ann Rheum Dis 2020 Background: Rheumatic and musculoskeletal immune-related adverse events (irAEs) are observed in about 10% of patients with cancer receiving checkpoint inhibitors (CPIs). Given… Read More

Cancer Immunol Immunother 2021
Limited data are available on the safety and efficacy of immune checkpoint inhibitors (ICI) in patients with preexisting autoimmune diseases… Read More

N Engl J Med 2018
A case of PR3-ANCA GPA developing after checkpoint blockade is described. Read More

Sci Rep 2020
The ‘real-world’ patient population of metastatic melanoma is not fully represented in clinical trials investigating checkpoint inhibitors. We described therapy discontinuation… Read More

Autoimmun Rev 2020
Objective: Although immune checkpoint inhibitors (ICI) have revolutionized cancer therapy, their use is associated with immune toxicities referred to as immune-related… Read More

Nat Rev Clin Oncol 2020
The enhancement of immune responses upon treatment with immune checkpoint inhibitors can have the desired outcome of reinvigorating antitumour… Read More

CMAJ 2020 Immune checkpoint inhibitors (ICI’s) are increasingly used in cancer immunotherapy, and have shown unprecedented survival benefit in a number of malignancies with historically… Read More

N Engl J Med 2020
A case description of the successful use of tofacitinib in a patient with gastric cancer receiving pembrolizumab whose… Read More

J Cancer Sci Therap 2019
Objectives: Immune checkpoint inhibitors (ICI) are associated with immune-related adverse events (irAE), including autoimmune rheumatologic diseases. The Canadian Research… Read More